Literature DB >> 20528555

Colorectal cancer: current care, future innovations and economic considerations.

David A L Macafee1, Elizabeth H Gemmill, John N Lund.   

Abstract

For those involved in colorectal cancer management, the present day is an exciting time. There is a multitude of new techniques to be considered for early detection (screening). National population screening for 60-69-year olds in England is due to start this year. Also, minimally invasive surgical techniques and multimodal pathways of care are aiding faster recovery, and there are increasing options for both adjuvant and palliative therapies. This article summarizes how colorectal cancer is currently managed in the UK and discusses the developments that are in the early stages of clinical use or on the horizon. Current management is discussed in detail in the hope that innovators reading the article may identify areas for improvement and allow comparison of new interventions with what are currently the gold standards. As changes are moving so fast, this review will probably only relate to the next 10 years at most. It does not provide a detailed reference list to support all therapies but indicates the key publications that will enable more detailed reading.

Entities:  

Year:  2006        PMID: 20528555     DOI: 10.1586/14737167.6.2.195

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  6 in total

1.  Colorectal cancer screening using the faecal occult blood test (FOBt): a survey of GP attitudes and practices in the UK.

Authors:  Sarah Damery; Sue Clifford; Sue Wilson
Journal:  BMC Fam Pract       Date:  2010-03-09       Impact factor: 2.497

2.  Evaluating the effectiveness of GP endorsement on increasing participation in the NHS Bowel Cancer Screening Programme in England: study protocol for a randomized controlled trial.

Authors:  Sarah Damery; Steve Smith; Alison Clements; Roger Holder; Linda Nichols; Heather Draper; Sue Clifford; Laura Parker; Richard Hobbs; Sue Wilson
Journal:  Trials       Date:  2012-02-20       Impact factor: 2.279

3.  Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test.

Authors:  S Wilson; S Damery; D D Stocken; G Dowswell; R Holder; S T Ward; V Redman; M J Wakelam; J James; F D R Hobbs; T Ismail
Journal:  Br J Cancer       Date:  2012-03-20       Impact factor: 7.640

4.  Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients.

Authors:  N G Hurst; D D Stocken; S Wilson; C Keh; M J O Wakelam; T Ismail
Journal:  Br J Cancer       Date:  2007-10-02       Impact factor: 7.640

5.  Factors affecting attitudes toward colorectal cancer screening in the primary care population.

Authors:  T Taskila; S Wilson; S Damery; A Roalfe; V Redman; T Ismail; R Hobbs
Journal:  Br J Cancer       Date:  2009-06-23       Impact factor: 7.640

6.  Establishing the added benefit of measuring MMP9 in FOB positive patients as a part of the Wolverhampton colorectal cancer screening programme.

Authors:  Sue Wilson; Taina Taskila; Tariq Ismail; Deborah D Stocken; Ashley Martin; Val Redman; Michael Wakelam; Ian Perry; Richard Hobbs
Journal:  BMC Cancer       Date:  2009-01-28       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.